Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Genmab A/S ADR (GMAB)

Genmab A/S ADR (GMAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 19,823,676
  • Shares Outstanding, K 661,230
  • Annual Sales, $ 2,392 M
  • Annual Income, $ 631,910 K
  • 60-Month Beta 1.00
  • Price/Sales 8.20
  • Price/Cash Flow 23.91
  • Price/Book 4.14
Trade GMAB with:

Options Overview Details

View History
  • Implied Volatility 67.93% ( +52.45%)
  • Historical Volatility 35.30%
  • IV Percentile 99%
  • IV Rank 95.90%
  • IV High 70.23% on 03/14/24
  • IV Low 14.29% on 05/10/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 5
  • Volume Avg (30-Day) 15
  • Put/Call OI Ratio 0.92
  • Today's Open Interest 1,136
  • Open Int (30-Day) 1,088

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate 0.28
  • Number of Estimates 7
  • High Estimate 0.33
  • Low Estimate 0.26
  • Prior Year 0.30
  • Growth Rate Est. (year over year) -6.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
27.42 +9.35%
on 05/02/24
30.41 -1.41%
on 05/15/24
+1.45 (+5.08%)
since 04/17/24
3-Month
27.42 +9.35%
on 05/02/24
31.88 -5.96%
on 03/13/24
+1.27 (+4.42%)
since 02/16/24
52-Week
26.32 +13.91%
on 02/13/24
42.72 -29.82%
on 07/28/23
-11.42 (-27.58%)
since 05/17/23

Most Recent Stories

More News
Forget Weight-Loss Drugs, Here's the Next Breakthrough Pharma Stock

There is another segment of the pharma industry that is as hot as weight-loss drugs: antibody-drug conjugates, or ADCs. These treatments will, in the near future, replace conventional chemotherapy, thanks...

PFE : 28.64 (-0.97%)
ABBV : 166.42 (+1.26%)
JNJ : 154.64 (+0.23%)
RHHBY : 32.8100 (+0.49%)
GMAB : 29.98 (+1.11%)
AZN : 76.90 (-0.18%)
DSNKY : 35.4950 (+1.47%)
MRK : 131.19 (+0.24%)
LLY : 770.00 (-0.15%)
NVO : 131.89 (-0.86%)
Why Shares of Iovance Biotherapeutics Dropped Thursday

The biotech stock's lead therapy is looking at some competition.

SGEN : 228.74 (-0.07%)
GMAB : 29.98 (+1.11%)
IOVA : 10.24 (-1.82%)
Why Shares of Zai Lab Limited Were Jumping on Tuesday

Zai Lab's shares benefited from positive clinical trial news.

ZLAB : 19.40 (-2.66%)
SGEN : 228.74 (-0.07%)
GMAB : 29.98 (+1.11%)
Is AbbVie Still a Good Dividend Stock to Buy?

Find out if AbbVie can overcome sinking sales of its top-selling product.

ABT : 104.09 (-0.74%)
RHHBY : 32.8100 (+0.49%)
AMGN : 312.47 (-0.71%)
GMAB : 29.98 (+1.11%)
ABBV : 166.42 (+1.26%)
3 Things About Johnson & Johnson Every Smart Investor Knows

The company has been a strong value stock but faces big changes this year.

KVUE : 20.47 (-0.63%)
AMGN : 312.47 (-0.71%)
GMAB : 29.98 (+1.11%)
JNJ : 154.64 (+0.23%)
Could This New Drug Be a Blockbuster for These 2 Pharma Collaborators?

In May, the FDA approved epcoritamab, developed by AbbVie and Genmab, as a treatment for a type of blood cancer.

ABBV : 166.42 (+1.26%)
GMAB : 29.98 (+1.11%)
AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

/PRNewswire/ -- AbbVie (NYSE: ABBV) and Genmab (Nasdaq: GMAB) today announced topline results from the follicular lymphoma (FL) cohort of the Phase 1/2 EPCOREâ„¢...

ABBV : 166.42 (+1.26%)
GMAB : 29.98 (+1.11%)
Strength Seen in Ultragenyx (RARE): Can Its 6.7% Jump Turn into More Strength?

Ultragenyx (RARE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road....

RARE : 41.87 (-1.74%)
GMAB : 29.98 (+1.11%)
Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology

Genmab A/S (Nasdaq: GMAB) and argenx (Euronext & Nasdaq: ARGX) announced today that Genmab and argenx have entered into a collaboration agreement to jointly discover, develop and commercialize novel...

GMAB : 29.98 (+1.11%)
Zacks.com featured highlights Genmab, Hologic, ServiceNow and Splunk

Genmab, Hologic, ServiceNow and Splunk have been highlighted in this Screen of The Week article.

HOLX : 75.02 (+0.09%)
SPLK : 156.90 (+0.25%)
NOW : 765.05 (+0.93%)
GMAB : 29.98 (+1.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Genmab A/S is a biotechnology company. It specializes in development of antibody therapeutics for the treatment of cancer. The company's product pipeline includes DARZALEX(R), Arzerra(R), tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5(R) and DuoBody-CD3xCD20 (R),which are in clinical stage....

See More

Key Turning Points

3rd Resistance Point 30.63
2nd Resistance Point 30.31
1st Resistance Point 30.15
Last Price 29.98
1st Support Level 29.67
2nd Support Level 29.35
3rd Support Level 29.19

See More

52-Week High 42.72
Fibonacci 61.8% 36.46
Fibonacci 50% 34.52
Fibonacci 38.2% 32.58
Last Price 29.98
52-Week Low 26.32

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar